Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

Expert Review of Anticancer Therapy

Volumn 9, Issue 5, 2009, Pages 663-670

  Atallah, Ehab ^a   Verstovsek, Srdan ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Essential thrombocythemia; JAK2 inhibitor; Myelofibrosis; Myeloproliferative neoplasm; Polycythemia vera

Indexed keywords

ANTINEOPLASTIC AGENT; ATIPRIMOD; CMP 6; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; EMODIN; ERLOTINIB; INCB 018424; ITF 2357; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; LESTAURTINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN MCL 1; SD 1008; STAT3 PROTEIN; TG 101348; UNCLASSIFIED DRUG; XL 019; ENZYME INHIBITOR;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; BLOOD TOXICITY; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FORMICATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEART PALPITATION; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOID METAPLASIA; NAUSEA; NAUSEA AND VOMITING; NERVE CONDUCTION DISORDER; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; POLYCYTHEMIA VERA; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH PAIN; THROMBOCYTOPENIA; THROMBOCYTOSIS; VOMITING; WEIGHT GAIN; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; MYELOPROLIFERATIVE DISORDER;

ENZYME INHIBITORS; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS;

EID: 68149160994     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.14     Document Type: Review

References (64)

1. Liu CB, Itoh T, Arai K, Watanabe S. Constitutive activation of JAK2 confers murine interleukin-3-independent survival and proliferation of BA/F3 cells. J. Biol. Chem. 274(10), 6342-6349 (1999).
2. Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood 93(7), 2369-2379 (1999).
3. Takemoto S, Mulloy JC, Cereseto A et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl Acad. Sci. USA 94(25), 13897-13902 (1997).
4. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (9464), 1054-1061 (2005).
5. James C Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037), 1144-1148 (2005).
6. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352(17), 1779-1790 (2005).
7. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4), 387-397 (2005).
8. Zhao R, Xing S, Li Z et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280(24), 22788-22792 (2005).
9. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am. Soc. Hematol. Educ. Program 240-245 (2006).
10. Passamonti F, Rumi E, Pungolino E et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am. J. Med. 117(10), 755-761 (2004).
11. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin. Proc. 79(7), 883-889 (2004).
12. Thomas DA, Giles FJ, Albitar M et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106(9), 1974-1984 (2006).
13. Tefferi A, Cortes J, Verstovsek S et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108(4), 1158-1164 (2006).
14. Deeg HJ, Gooley TA, Flowers MED et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102(12), 3912-3918 (2003).
15. Cervantes F, Dupriez B, Pereira A et al. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13), 2895-2901 (2008).
16. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 5(12), 253 (2004).
17. Bittorf T, Jaster R, Ludtke B, Kamper B, Brock J. Requirement for JAK2 in erythropoietin-induced signalling pathways. Cell Signal. 9(1), 85-89 (1997).
18. Sattler M, Durstin MA, Frank DA et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp. Hematol. 23(9), 1040-1048 (1995).
19. Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L. Granulocyte - macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. J. Biol. Chem. 271(7), 3562-3567 (1996).
20. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93(3), 397-409 (1998).
21. Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93(3), 385-395 (1998).
22. Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7(7), 1347-1353 (1992).
23. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277(49), 47954-47963 (2002).
24. Wernig G, Kharas MG, Okabe R et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13(4), 311-320 (2008).
25. Pardanani AD, Gotlib J, Jamieson C et al. A Phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 97).
26. Verstovsek S, Kantarjian HM, Pardanani AD et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post PV/ETMF). ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 1762).
27. Mesa RA, Schwager S, Radia D et al. Assessment and monitoring of constitutional symptoms in patients with myelofibrosis: a proposed new instrument the myelofibrosis symptom assessment form (MFSAF). ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 1754).
28. Tefferi A, Kantarjian HM, Pardanani AD et al. The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 2804).
29. Verstovsek S, Kantarjian HM, Pardanani AD et al. Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F:WT JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with the JAK inhibitor, INCB018424. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 2802).
30. Paquette R, Sokol L, Shah NP et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 2810).
31. Shah NP, Olszynski P, Sokol L et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 98).
32. Guerini V, Barbui V, Spinelli O et al. Selective targeting of the JAK2V617F mutation in polycythemia vera and essential thrombocythemia by ITF2357, a novel histone deacetylase inhibitor. ASH Annual Meeting Abstracts, 110(11) (2007) (Abstract 555).
33. Rambaldi A, Dellacasa CM, Salmoiraghi S et al. A Phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 100).
34. Giles F, Bergstrom DA, Garcia-Manero G et al. MK-0457 is a novel aurora kinase and janus kinase 2 (JAK2) inhibitor with activity in transformed JAK2-positive myeloproliferative disease (MPD). ASH Annual Meeting Abstracts 108(11) (2006) (Abstract 4893).
35. Levis M, Smith BD, Beran M et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. ASH Annual Meeting Abstracts 106(11) (2005) (Abstract 403).
36. Dobrzanski P, Hexner E, Serdikoff C et al. CEP-701 is a JAK2 inhibitor which attenuates jak2/stat5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders. ASH Annual Meeting Abstracts 108(11) (2006) (Abstract 3594).
37. Moliterno AR, Roboz GJ, Carroll M, Luger S, Hexner E, Bensen-Kennedy DM. An open-label study of cep-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 99).
38. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21(12), 2237-2246 (2003).
39. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
40. Li Z, Xu M, Xing S et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J. Biol. Chem. 282(6), 3428-3432 (2007).
41. Albrightson-Winslow CR, Brickson B, King A et al. Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis. J. Pharmacol. Exp. Ther. 255(1), 382-387 (1990).
42. Amit-Vazina M, Shishodia S, Harris D et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br. J. Cancer 93(1), 70-80 (2005).
43. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk. Res. 31(1), 91-95 (2007).
44. Duan Z, Bradner J, Greenberg E et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1] oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol. Pharmacol. 72(5), 1137-1145 (2007).
45. Lucet IS, Fantino E, Styles M et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107(1), 176-183 (2006).
46. Thompson JE, Cubbon RM, Cummings RT et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12(8), 1219-1223 (2002).
47. Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Mol. Cancer Ther. 7(8), 2308-2318 (2008).
48. Grandage VL, Everington T, Linch DC, Khwaja A. Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br. J. Haematol. 135(3), 303-316 (2006).
49. Muto A, Hori M, Sasaki Y et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol. Cancer Ther. 6(3), 987-994 (2007).
50. Meydan N, Grunberger T, Dadi H et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379(6566), 645-648 (1996).
51. Duek A, Lichman I, Shtalrid M, Berrebi A. The Jak2-inhibitor AG409 affects survival of BFU-E and CFU-GM of myeloproliferative disorder cells carrying the JAK2 V617F mutation. ASH Annual Meeting Abstracts, 108(11) (2006) (Abstract 4907).
52. Kapuria V, Bartholomeusz G, Kong L-Y et al. A novel small-molecule approach to inhibit Jak2 tyrosine kinase signaling. ASH Annual Meeting Abstracts 110(11) (2007) (Abstract 1556).
53. Manshouri T, Estrov Z, Quintas-Cardama A et al. WP1066 inhibits growth of human cells carrying the JAK2 V617F mutation. ASH Annual Meeting Abstracts 108(11) (2006) (Abstract 4885).
54. Ferrajoli A, Faderl S, Wang T et al. WP1066: a novel PI-3K inhibitor with antileukemic activity in philadelphia chromosome-positive ALL. ASH Annual Meeting Abstracts 106(11) (2005) (Abstract 850).
55. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk. Res. 30(11), 1457-1460 (2006).
56. Theocharides A, Boissinot M, Girodon F et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1), 375-379 (2007).
57. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7), 1299-1307 (2008).
58. Epling-Burnette PK, Liu JH, Catlett-Falcone R et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107(3), 351-362 (2001).
59. Dohner K, Du J, Corbacioglu A, Scholl C, Schlenk RF, Dohner H. JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. Haematologica 91(11), 1569-1570 (2006).
60. Lo M-C, Peterson LF, Yan M et al. Identification of the JAK/STAT signaling pathway as a valid therapeutic target of t(8;21) acute myeloid leukemia using combined gene expression and promoter occupancy profiling. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 3336).
61. Schnittger S, Bacher U, Kern W, Haferlach C, Haferlach T. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML. Leukemia 21(1), 183-184 (2007).
62. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Jak2: a potential therapeutic target for chronic myelogenous leukemia (CML). ASH Annual Meeting Abstracts 108(11) (2006) (Abstract 2121).
63. Sun X, Layton JE, Elefanty A, Lieschke GJ. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL - expressing cells, demonstrating synergy between AG490 and STI571. Blood 97(7), 2008-2015 (2001).
64. Fridman J, Nussenzveig R, Liu P et al. Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders. ASH Annual Meeting Abstracts 110(11) (2007) (Abstract 3538).